Current Drug Delivery

Istvan Toth
School of Pharmacy,University of Queensland
Brisbane, 4072


Highly Immunogenic Trimethyl Chitosan-Based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus

(E-pub Ahead of Print)

Author(s): Nirmal Marasini, Khairunnisa Abdul Ghaffar, Ashwini Kumar Giddam, Michael R Batzloff, Michael F Good, Mariusz Skwarczynski, Istvan Toth.


Group A streptococcus (GAS) infections can led to a large variety of diseases in humans including the most common acute pharyngitis. If untreated, GAS infections lead to life- threatening conditions such as rheumatic heart diseases and post-streptococcal glomerulonephritis. GAS primarily colonises the mucosal region of the upper respiratory tract, slowly leading to systemic infections. Thus, GAS-specific antibody responses are desirable at mucosal sites for early prevention against GAS colonisation. Although several GAS vaccines are currently in clinical trials, these vaccines aim to stimulate systemic immunity, not mucosal immunity, thus will not protect against colonization. Herein, we developed a potent nanoliposomes-based delivery system for mucosally active lipid core peptide (LCP)-based vaccines. Trimethyl chitosan (TMC)-coated liposomes that bore a B-cell epitope derived from GAS M-protein, stimulated potent epitope-specific mucosal and systemic antibody titres after only one boost following intranasal immunisation in Swiss outbred mice. The immune responses were durable even at day 139 post-primary immunisation. The enhanced vaccine efficacy, lowered dose, and simple and cost-effective process of producing the coated nanoliposomes should be particularly useful in developing potent peptide-based vaccines to prevent infections at the mucosal sites.

Keywords: lipopeptides; peptide vaccines; nasal delivery; chitosan; liposomes; group A streptococcus

Rights & PermissionsPrintExport

Article Details

Year: 2016
(E-pub Ahead of Print)
DOI: 10.2174/1567201813666160721141322
Price: $95